Canagliflozin
Brand: Invokana (US/EU) / Cana (IN/BD)
Antidiabetic
SGLT2 inhibitor
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 1 h |
| Bioavailability | 65 % (approx) |
| Protein Binding | 99 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | no |
| Notes | Start 100 mg od; consider 300 mg if tolerated and renal function adequate; amputation risk signal reported in some data. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Genital mycotic infection, polyuria, volume depletion, euglycemic DKA (rare), ↑fracture/amputation signal
Contraindications:
Dialysis
Precautions:
Hydration counseling; sick-day rules; monitor feet in high-risk patients